Aneurysm occlusion device

Information

  • Patent Grant
  • 11154302
  • Patent Number
    11,154,302
  • Date Filed
    Monday, March 31, 2014
    10 years ago
  • Date Issued
    Tuesday, October 26, 2021
    2 years ago
Abstract
An occlusion device suitable for endovascular treatment of an aneurysm in a blood vessel in a patient, including a substantially tubular structure having a proximal end region and a distal end region, having a first, expanded condition and a second, collapsed condition. The device has dimensions in the second, collapsed condition suitable for insertion through vasculature of the patient and through a neck of the aneurysm. The device further includes a control ring having a substantially annular body disposed on the proximal end region of the structure and at least substantially circumscribing the proximal end region to prevent radial expansion of the proximal end region and to provide an engagement feature during manipulation of the occlusion device.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention

The invention relates to implants within body vessels and more particularly to occlusion devices for small vascular openings such as a neck of an aneurysm.


2. Description of the Related Art

Vascular disorders and defects such as aneurysms and other arterio-venous malformations are especially difficult to treat when located near critical tissues or where ready access to a malformation is not available. Both difficulty factors apply especially to cranial aneurysms. Due to the sensitive brain tissue surrounding cranial blood vessels and the restricted access, it is very challenging and often risky to surgically treat defects of the cranial vasculature.


In the treatment of aneurysms by endovascular implants, the goal is to exclude the internal volume of the aneurysm sac from arterial blood pressure and flow. As long as the interior walls of the aneurysm are subjected to blood pressure and/or flow, there is a risk of the aneurysm rupturing.


Non-surgical treatments include vascular occlusion devices such as embolic coils deployed using catheter delivery systems. In a currently preferred procedure to treat a cranial aneurysm, the distal end of an embolic coil delivery catheter is initially inserted into non-cranial vasculature of a patient, typically through a femoral artery in the groin, and guided to a predetermined delivery site in a blood vessel within the cranium. The aneurysm sac is then filled with embolic material that causes formation of a solid, thrombotic mass that protects the walls from blood pressure and flow. Preferably, the thrombotic mass substantially restores the original blood vessel shape along the plane of the aneurysm's neck. The neck plane is an imaginary surface where the intima of the blood vessel would be if not for formation of the aneurysm. However, simply utilizing embolic coils is not always effective at treating aneurysms as re-canalization of the aneurysm and/or coil compaction can occur over time.


A bag for use in an aneurysm sac is described by Greenhalgh in U.S. Pat. Nos. 6,346,117 and 6,391,037, and an aneurysm neck obstruction device is shown in U.S. Pat. No. 6,454,780 by Wallace. Detachable neck bridges are disclosed by Abrams et al. in U.S. Pat. No. 6,036,720 and by Murphy et al. in U.S. Pat. No. 7,410,482 for example. Preferably, one or more embolic coils are delivered within or through the neck bridges or other obstruction devices to fill the sac of the aneurysm.


Yet another type of vaso-occlusive device is illustrated in U.S. Pat. No. 5,645,558 by Horton as having one or more strands of flexible material which are wound to form a generally spherical or ovoid vaso-occlusive structure when relaxed after being placed in a vascular cavity such as an aneurysm or fistula. Similarly, U.S. Pat. No. 5,916,235 by Guglielmi cites earlier patents describing detachable coils and then discloses an expandable cage as a vaso-occlusive structure that can receive and retain one or more coils after the cage is expanded within an aneurysm. A self-expandable aneurysm filling device is disclosed in US Patent Publication No. 2010/0069948 by Veznedaroglu et al.


It is therefore desirable to have a retrievable, repositionable device that cooperates with one or more embolic coils or other vaso-occlusive structure to effectively occlude a neck of an aneurysm or other arterio-venous malformation in a blood vessel.


SUMMARY OF THE INVENTION

An object of the present invention is to provide an improved occlusion device which substantially blocks flow into an aneurysm in a blood vessel.


Another object of the present invention is to provide such an occlusion device which can be repositioned or retrieved from a sac of an aneurysm.


This invention features an occlusion device suitable for endovascular treatment of an aneurysm in a blood vessel in a patient, including a substantially tubular structure having a proximal end region and a distal end region, having a first, expanded condition and a second, collapsed condition. The device has dimensions in the second, collapsed condition suitable for insertion through vasculature of the patient and through a neck of the aneurysm. The device further includes a control ring having a substantially annular body disposed on the proximal end region of the structure and at least substantially circumscribing the proximal end region to prevent radial expansion of the proximal end region and to provide an engagement feature during manipulation of the occlusion device.


In a number of embodiments, the control ring defines an inner passage, such as a channel established by an inner sleeve, through which at least one embolic coil is insertable into the aneurysm. Preferably, at least a portion of the proximal end region of the tubular structure defines a plurality of openings having a sufficiently small size to enhance occlusion of the aneurysm. In some embodiments, the tubular structure cooperates with at least one vaso-occlusion structure such as a collapsible cage-like device.


In certain embodiments, the occlusive device is capable of being utilized in combination with a delivery member defining an inner lumen and having a distal end region carrying a grabber having at least two finger elements, each finger element defining a gripping region to mechanically engage the control ring. In one embodiment, the grabber is formed of a metallic material and the gripping regions are notches formed in the finger elements, each notch being sized to mechanically engage a portion of the control ring. The combination may further include a catheter having an inner lumen through which the delivery tube is insertable and translatable relative to the catheter.


This invention may also be expressed as a method of treating an aneurysm in a blood vessel in a patient, the method including selecting an occlusion device with a structure having a substantially tubular structure having a proximal end region and a distal end region, having a first, expanded condition and a second, collapsed condition, and having dimensions in the second, collapsed condition suitable for insertion through vasculature of the patient and through a neck of the aneurysm. The device further includes a control ring having a substantially annular body disposed on the proximal end region of the structure and at least substantially circumscribing the proximal end region to prevent radial expansion of the proximal end region.


In some embodiments, the method further includes mechanically engaging the control ring with a grabber on a delivery tube to enable manipulation of the occlusion device, drawing the occlusion device into a catheter carrying the delivery tube to force the occlusion device into the collapsed condition, inserting the catheter with the occlusion device into vasculature of the patient to reach the region of the aneurysm in the blood vessel, and positioning the occlusion device within the aneurysm.


In certain embodiments, the method additionally includes delivering at least one embolic coil through the delivery tube and through the control ring to secure the occlusion device within the aneurysm to occlude flow into the aneurysm, and mechanically releasing the control ring and withdrawing the catheter and the delivery tube from the patient. In yet other embodiments, the method further includes selecting the occlusive device to be attached to a collapsible cage-like vaso-occlusive structure, and positioning the occlusive device within the aneurysm includes utilizing the vaso-occlusive structure to secure the proximal end region of the tubular structure across the neck of the aneurysm





BRIEF DESCRIPTION OF THE DRAWINGS

In what follows, preferred embodiments of the invention are explained in more detail with reference to the drawings and photographs, in which:



FIG. 1 is a schematic side cross-sectional view of an inventive occlusion device within a novel catheter delivery system positioned at the neck of an aneurysm of a blood vessel;



FIG. 2 is an enlarged schematic side view of the delivery system of FIG. 1 showing the occlusion device held in a collapsed condition;



FIG. 3 is a schematic side view similar to FIG. 1 showing the occlusion device according to the present invention expanding within the sac of the aneurysm while still being securely held by the delivery system;



FIG. 4 is a schematic side view similar to FIG. 3 showing an embolic coil being advanced through the delivery system and the occlusion device into the aneurysm;



FIG. 5 is a schematic side view similar to FIG. 2 with the microcatheter withdrawn proximally to allow grasper fingers to release the control ring of the occlusion device;



FIG. 6 is a schematic side cross-sectional view similar to FIG. 4 after the delivery system has been withdrawn and with embolic coils securing the occlusion device within the sac of the aneurysm;



FIG. 7 is a schematic cross-sectional view of a spherical mandrel establishing the first, expanded condition for at least one an occlusion device according to the present invention;



FIGS. 8A and 8B are schematic side views of two hemi-spherical occlusion devices according to the present invention derived from the occlusion device of FIG. 7;



FIG. 9 is a schematic side view of a single occlusion device after the mandrel of FIG. 7 has been removed;



FIG. 10 is a schematic side view similar to FIG. 9 after a distal portion of the occlusion device has been removed to generate an alternative open configuration;



FIG. 11 is a side view similar to FIG. 10 of an alternative occlusion device formed utilizing an elliptical, lozenge-shaped mandrel;



FIG. 12 is a view similar to FIG. 3 showing the occlusion device cooperating with a cage-like vaso-occlusive structure within an aneurysm;



FIG. 13 is an enlarged schematic side view of an alternative delivery system for devices similar to those shown in FIG. 12 with an occlusion device and a vaso-occlusive structure held in a collapsed condition being advanced into an aneurysm; and



FIG. 14 is a schematic side cross-sectional view similar to FIG. 13 after the delivery system has been withdrawn, and with the vaso-occlusive structure securing the occlusion device within the sac of the aneurysm.





DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

This invention may be accomplished by an occlusion device suitable for endovascular treatment of an aneurysm in a blood vessel in a patient, with a substantially tubular structure having a proximal end region and a distal end region, having a first, expanded condition and a second, collapsed condition. The device has dimensions in the second, collapsed condition suitable for insertion through vasculature of the patient, utilizing a catheter such as a microcatheter, and through a neck of the aneurysm. The device further includes a control ring having a substantially annular body disposed on the proximal end region of the structure and at least substantially circumscribing the proximal end region to prevent radial expansion of the proximal end region and to provide an engagement feature during manipulation of the occlusion device.


The control ring is releasably engagable by a releasable feature such as a grabber or at least one frangible member on a delivery member in some mechanical constructions or, in other constructions, by at least one electrolytically severable element. Preferably, the control ring defines an inner passage through which at least one embolic coil is insertable into the aneurysm. In another construction, the occlusion device is held in place within the aneurysm by at least one vaso-occlusive structure such as a cage-like device.



FIG. 1 schematically illustrates the distal portion of a novel delivery system 10 including a microcatheter 12 and a delivery tube 14 holding a tubular occlusion device 20 according to the present invention to be implanted within sac S of aneurysm A emerging from blood vessel BV. In one construction, the microcatheter 12 has a distal radiopaque marker band 13 and is advanced to the vicinity of neck N of aneurysm A such that marker band 13 is at the level of the neck N as seen under fluoroscopy.


Enlarged views of the distal portion of delivery system 10 and of occlusion device 20 are provided in FIGS. 2 and 5. Occlusion device 20 is shown in a second, collapsed condition in FIG. 2 within catheter lumen 11, with a control ring 22 held by grabber 30 of delivery tube 14. Control ring 22 is disposed about a proximal region 23 of device structure 25 and defines an inner passage 26 through which one or more embolic coils are inserted, as described in more detail below. Structure 25 of occlusion device 20 further includes a mesh body 24 and a distal region 28.


After the delivery system 10 is positioned as shown in FIG. 1, the delivery tube 14 is advanced within lumen 11 of catheter 12 to enable occlusion device 20 to expand into an approximately hemi-spherical shape within sac S as shown in FIG. 3. The shape of occlusion device 20 will conform to the shape of the sac S where device 20 touches the inner wall of the sac S. Grabber 30 continues to be constrained radially by lumen 11 of catheter 12 and maintains its grip on control ring 22 with a plurality of gripping regions such as notches 36 and 38, FIG. 5. In one construction, control ring 22 is radiopaque and is aligned under fluoroscopy relative to marker 13 on catheter 12 as shown in FIGS. 3 and 4.


Once occlusion device 20 is positioned within sac S, at least one embolic coil 40, FIG. 4, is advanced through lumen 15 of delivery tube 14 as indicated by arrow 42, through passage 26 of control ring 22 as indicated by arrow 44, and is advanced, arrow 46, within aneurysm A to substantially fill sac S and to anchor body 24 of occlusion device 20 against the interior wall of aneurysm A to block neck N as shown in FIG. 6.


After a sufficient amount of embolic coil 40 has been fully deployed within sac S to anchor occlusion device 20 within aneurysm A, the catheter 12 is withdrawn proximally, as indicated by arrow 51 in FIG. 5, while maintaining delivery tube 14 in place, to remove radial constraint on fingers 32 and 34 of grabber 30. Fingers 32 and 34 preferably are biased radially outwardly and move in the direction of arrows 50 and 52, respectively, to disengage control ring 22 from notches 36 and 38 in fingers 32 and 34, respectively.


In one construction, the catheter 12 is a polymeric microcatheter defining an inner lumen 11 having an inner diameter of between 0.020 inch and 0.027 inch, the delivery tube 14 has outer diameter that is slightly less than the inner diameter of the catheter lumen 11, and the grabber 30 with occlusion device 20 in the collapsed condition shown in FIGS. 1 and 2 also have outer diameters that are substantially the same as the inner diameter of the catheter lumen 11, which radially constrains fingers 32 and 34 to engage control ring 22. The lumen 15 of delivery tube 14 has a diameter capable of allowing passage of a conventional embolic coil delivery system having a nominal outer diameter of between 0.010 inch and 0.015 inch.


In some constructions, the delivery tube has at least one region of increased flexibility, especially near the distal end of the delivery tube, to minimize unintended microcatheter movement during translation of the delivery tube relative to the microcatheter. The at least one flexible region is made in one construction by laser-cutting a pattern of interrupted cuts into a medical-grade nitinol (NiTi) tube. In other constructions, a coiled metallic or polymeric cylindrical component and/or a cylindrical section of flexible polymeric material is added to the distal region of the delivery tube. The grabber is created in some constructions by laser-cutting material forming the grabber to create at least two finger elements, each preferably having a notch to enhance gripping of a control ring according to the present invention. In certain constructions, the grabber is integral, that is, is monolithically formed with the same material as the remainder of the delivery tube and, in other constructions, is fixedly attached to the distal end of the delivery tube.


In one construction, the structure 25 of occlusion device 20 is formed of metallic filaments that establish an expandable braided mesh tube. Suitable materials for the filaments include nitinol wires and other biocompatible metals, such as platinum, that will not remain in a collapsed condition after being ejected from a delivery tube. Preferably, at least one platinum wire is included for radiopacity. In other constructions, the structure 25 is formed of at least one polymeric material that does not become “set” in the collapsed condition.


Suitable materials for control ring 22 discussed above, and for control ring 22a and band 22b discussed below in relation to FIGS. 7-8B, include biocompatible radiopaque materials such as platinum, tantalum and gold. Other suitable metallic materials include cobalt chromium, stainless steel, and combinations of two or more of biocompatible metals. Suitable polymeric materials include biocompatible biodegradable and non-biodegradable materials, as described in more detail below.


One technique for manufacturing an occlusion device according to the present invention is illustrated in FIG. 7. After structure 25a is formed as a braided mesh tube, a control ring 22a is disposed by crimping and/or welding ring material about proximal region 23a to limit radial expansion at that site while defining an inner passage 26a through which one or more embolic coils can be inserted, as described above. Optionally, an inner sleeve such as a grommet (not shown) is inserted within structure 25a and positioned under the control ring 23a to maintain an inner diameter opening of desired dimension for inner passage 26a.


In this technique, a spherical mandrel 60 such as a steel ball bearing is inserted through distal region 28a to enlarge and expand the structure 25a in body region 24a. A clamp-like element such as a band 22b is then crimped over distal region 62 to further shape the body 24a. In some techniques, the assembly is heated to set mesh body 24a in the expanded condition.


When two hemispherical occlusion devices are desired, a cut is made along the circumference of mandrel 60, typically equidistant between control ring 22a and band 22b as indicated by dashed line 63, as well as on the opposite sides of control ring 22a and band 22b as shown by arrows 64 and 66, respectively. This technique creates two separate devices 20a and 20b, as depicted in FIGS. 8A and 8B, respectively. Distal end regions 28a and 28b are both open, such as illustrated for device 20 in FIGS. 1-6. Device 20b also has body 24b, proximal region 23b, and a passage 26b formed by band 22b which serves as a control ring according to the present invention. In other words, band 22b is incorporated into an implantable device 20b in one construction, instead of being a temporary clamp.


In alternative techniques, band 22b is removed and mandrel 60, FIG. 7, is extracted to form the occlusion device 20c, FIG. 9, with a constricted yet un-constrained distal region 28c, having a single control ring 22a. In yet another technique, a cut is made non-equatorially about structure 25a, such as along line 70, to generate device 20d, FIG. 10. In yet other constructions, a non-spherical mandrel such as a lozenge-shaped mandrel, is utilized to form an elongated device 20e, FIG. 11. In other words, the occlusion device according to the present invention can have many shapes such as round, elliptic, oblong, or otherwise asymmetric, and can have an open or a closed distal end. It is expected that an open distal end will typically allow better conformance to the neck and sac of the aneurysm to be treated.


An alternative occlusion device 20f according the present invention is illustrated in FIG. 12 cooperating with a cage-like vaso-occlusive structure 80 formed of strands 82, 84, 86, 88, 90, 92 and 94 in this construction. In some constructions, vaso-occlusive structure 80 is similar to one of the embodiments disclosed in U.S. Pat. No. 5,645,558 by Horton and, in certain other constructions, is similar to one of the embodiments disclosed in U.S. Pat. No. 5,916,235 by Guglielmi and in US Patent Publication No. 2010/0069948 by Veznedaroglu et al.


After a delivery system 10f is positioned as desired relative to aneurysm A, an elongated delivery member 14f is advanced within lumen 11f of catheter 12f to enable occlusion device 20f and vaso-occlusive structure 80 to expand within sac S as shown in FIG. 12. In this construction, a grabber 30f continues to be constrained radially by lumen 11f of catheter 12f and maintains its grip on control ring 22f with a plurality of gripping regions. In one construction, control ring 22f is radiopaque and is aligned under fluoroscopy in a similar manner as described above relative to FIGS. 3 and 4.


Once vaso-occlusive structure 80 is fully deployed in an expanded condition within sac S, structure 80 presses occlusion device 20f against the interior wall and across the neck N of aneurysm A to secure it in place. In other words, vaso-occlusive structure 80 serves in an expanded condition as a frame or lattice to anchor occlusion device 20f against neck N, and occlusion device 20f, held in place by structure 80, serves as a cover extending at least across neck N, the cover preferably being porous or otherwise defining sufficiently small openings, to enhance occlusion of aneurysm A. Preferably, occlusion device 20f is secured to vaso-occlusive structure 80 by at least one attachment point, being attached to at least one of a portion of the interior surface of device 20f and a portion of the control ring 22f, to maintain an aligned relationship between the device 20f and the structure 80, especially during loading and delivery of structure 80 and device 20f utilizing a delivery cannula.


In certain techniques, if a surgeon or other user desires to substantially fill the interior of sac S, at least one embolic coil is advanced through lumen 15f of delivery tube 14f, through a passage in control ring 22f, and then is advanced into aneurysm A. In other constructions, for use where insertion of one or more embolic coils is not desired, control ring 22f may lack a passage.


In yet other constructions, such as illustrated in FIGS. 13-14, an occlusion device 20g has a detachment feature 98, representing a conventional detachment joint, instead of a control ring. Examples of electrolytically severable joints and mechanical joints are described in U.S. Pat. No. 6,454,780 by Wallace and in U.S. Pat. No. 7,410,482 by Murphy et al., for example. Similar detachable joints are described in U.S. Pat. No. 5,916,235 by Guglielmi for cage-like vaso-occlusive structures.


After the delivery system 10g is positioned within blood vessel BV as shown in FIG. 13, a delivery member 14g, also referred to as a pusher 14g, is advanced within lumen 11g of catheter 12g to enable occlusion device 20g and vaso-occlusive structure 80g to expand within aneurysm A as shown in FIG. 14. The connection between severable element 96 and detachment feature 98 is then severed, mechanically and/or electrolytically.


Body 24g is formed of a wire mesh or braid in some constructions. In yet other constructions, the body of the occlusive device is a biocompatible film made from one or more polymeric substances. Suitable biocompatible compositions for film material include films or matrices of cellulose, alginate, cross-linked gels, and very thin polymer films of materials such as urethane, polycaprolactone (PCL), poly-lactic acid (PLA) and/or poly-glycolic acid (PGA). The film need not be erodible or bioabsorbable. In some constructions, microscopic pores or other openings are formed in the film having average diameters which are uniform in some constructions and non-uniform in other constructions. The geometric size of the pores is substantially constant along the length of the structure in some embodiments and, in other embodiments, varies along the length. The number of pores is substantially uniform along the length of the structure in some embodiments and, in other embodiments, varies along the length. Other potential materials include polysaccharides, colloidal compounds, and some lipid products. In an alternate configuration, at least the body of the occlusive device is made of a durable, non-erodible, non-bioabsorbable material, such as a solidified urethane foam or expanded polytetrafluoroethylene (PTFE). In some embodiments, the material defines openings at least 10 microns in diameter prior to implantation in the patient and has a thickness ranging between 10 microns to 500 microns.


Thus, while there have been shown, described, and pointed out fundamental novel features of the invention as applied to a preferred embodiment thereof, it will be understood that various omissions, substitutions, and changes in the form and details of the devices illustrated, and in their operation, may be made by those skilled in the art without departing from the spirit and scope of the invention. For example, it is expressly intended that all combinations of those elements and/or steps that perform substantially the same function, in substantially the same way, to achieve the same results be within the scope of the invention. Substitutions of elements from one described embodiment to another are also fully intended and contemplated. It is also to be understood that the drawings are not necessarily drawn to scale, but that they are merely conceptual in nature. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.


Every issued patent, pending patent application, publication, journal article, book or any other reference cited herein is each incorporated by reference in their entirety.

Claims
  • 1. An occlusion device system suitable for endovascular treatment of an aneurysm in a blood vessel in a patient, comprising: an occlusion device comprising: a substantially tubular structure comprising: a proximal end region,a distal end region,a first, expanded condition, anda second, collapsed condition comprising dimensions suitable for insertion through vasculature of the patient and through a neck of the aneurysm,the tubular structure comprising an exterior surface capable of contacting the aneurysm in the expanded condition and having an interior surface,the tubular structure being a braided mesh tube, the tubular structure having a hemispherical shape in the expanded condition, andthe tubular structure being self-expanding to the expanded condition;a control ring having a substantially annular body disposed on the proximal end region of the tubular structure and at least substantially circumscribing the proximal end region to prevent radial expansion of the proximal end region and to provide an engagement feature during manipulation of the occlusion device;a delivery member comprising: an inner lumen; anda distal end region carrying a tubular grabber comprising at least two finger elements, each finger element comprising a notch having an inner top surface and an inner bottom surface defining an inner cavity having a height approximately equal to a thickness of the control ring such that the notch receives at least a portion of the control ring and thereby engages the control ring to the grabber; anda catheter comprising: a uniform inner diameter; anda catheter lumen sized from the inner diameter and configured to: completely enclose the substantially tubular structure, the control ring, and the grabber when the tubular structure is in the collapsed condition;constrict the grabber around the control ring so that the control ring is engaged within the notch of each finger element when at least a portion of the grabber is positioned within the catheter lumen; andallow the grabber to expand to disengage the control ring from the grabber once at least a portion of the grabber is outside the catheter lumen.
  • 2. The occlusion device system of claim 1 wherein the control ring and the tubular grabber define an inner passage through which at least one embolic coil is insertable into the aneurysm.
  • 3. The occlusion device system of claim 2 wherein the control ring includes an inner sleeve to define the inner passage.
  • 4. The occlusion device system of claim 1 wherein the control ring is crimped onto the proximal end region.
  • 5. The occlusion device system of claim 1 wherein the control ring includes radiopaque material.
  • 6. The occlusion device system of claim 1 wherein the tubular structure includes a plurality of filaments.
  • 7. The occlusion device system of claim 1 wherein the tubular structure defines a substantially enclosed volume.
  • 8. The occlusion device system of claim 1 wherein at least a portion of the proximal end region of the tubular structure defines a plurality of openings having a sufficiently small size to enhance occlusion of the aneurysm.
  • 9. The occlusion device of claim 1 further including a collapsible cage-like vaso-occlusive structure attached to at least one of a portion of the interior surface of the tubular structure and a portion of the control ring.
  • 10. The occlusion device system of claim 1 wherein the delivery member is a tube formed of at least one metallic material.
  • 11. The occlusion device system of claim 1 wherein the grabber is formed of a metallic material.
  • 12. The occlusion device system of claim 1, wherein the tubular grabber is integral with the delivery tube.
  • 13. A method of treating an aneurysm in a blood vessel in a patient, comprising: selecting an occlusion device comprising a substantially tubular structure having a proximal end region and a distal end region, having a first, expanded condition and a second, collapsed condition when drawn into a delivery catheter, and further including a control ring having a substantially annular body disposed on the proximal end region of the tubular structure and at least substantially circumscribing the proximal end region to prevent radial expansion of the proximal end region, the tubular structure being a braided mesh tube, the tubular structure having a hemispherical shape in the expanded condition;inserting the control ring into a notch of a finger element of a tubular grabber disposed at a distal end region of a delivery tube thereby engaging the control ring to the grabber, the notch having an inner top surface and an inner bottom surface defining an inner cavity having a height approximately equal to a thickness of the control ring;drawing the occlusion device engaged with the delivery tube into the delivery catheter to force the occlusion device into the collapsed condition;constraining the entire grabber in the delivery catheter;inserting the delivery catheter with the occlusion device into vasculature of the patient to reach the region of the aneurysm in the blood vessel;positioning the occlusion device within the aneurysm;partially withdrawing the delivery catheter to allow the braided mesh tube to self-expand to the expanded condition; andreleasing the control ring from the notch and completely withdrawing the delivery catheter and the delivery tube from the patient comprising the step of extending the delivery tube so as the grabber is distal of the delivery catheter.
  • 14. The method of claim 13 wherein the tubular structure includes braided filaments.
  • 15. The method of claim 13 further including delivering at least one embolic coil through the delivery catheter and through the control ring to secure the occlusion device within the aneurysm to occlude flow into the aneurysm.
  • 16. The method of claim 13 further comprising: mechanically engaging the control ring with the grabber to enable manipulation of the occlusion device, andutilizing the grabber to draw the occlusion device into the delivery catheter carrying the delivery tube to force the occlusion device into the collapsed condition.
  • 17. The method of claim 13 further including selecting the occlusive device to be attached to a collapsible cage-like vaso-occlusive structure, and positioning the occlusive device within the aneurysm includes utilizing the vaso-occlusive structure to secure the proximal end region of the tubular structure across the neck of the aneurysm.
  • 18. A method of treating an aneurysm in a blood vessel in a patient, comprising: selecting an occlusion device including a substantially tubular structure having a proximal end region and a distal end region, having a first, expanded condition and a second, collapsed condition when drawn into a microcatheter with a uniform diameter, at least a portion of the proximal end region defining a plurality of openings having a sufficiently small size to enhance occlusion of the aneurysm, and further including a control ring having a substantially annular body disposed on the proximal end region of the tubular structure and at least substantially circumscribing the proximal end region to prevent radial expansion of the proximal end region, the tubular structure is a braided mesh tube, the tubular structure having a hemispherical shape in the expanded condition;inserting the control ring into one or more notches of a tubular grabber on a delivery tube to enable manipulation of the occlusion device, the one or more notches having an inner top surface and an inner bottom surface defining an inner cavity having a height approximately equal to a thickness of the control ring, and drawing the entirety of the grabber into the microcatheter;drawing the occlusion device engaged with the delivery tube into the microcatheter carrying the delivery tube to force the occlusion device into the collapsed condition;inserting the microcatheter with the occlusion device into vasculature of the patient to reach the region of the aneurysm in the blood vessel;positioning the occlusion device within the aneurysm;partially withdrawing the microcatheter to allow the braided mesh tube to self-expand to the expanded condition;delivering at least one embolic coil through the delivery tube and through the control ring to secure the occlusion device within the aneurysm to occlude flow into the aneurysm;mechanically releasing the control ring by extending the grabber outside the microcatheter, thereby causing the grabber to expand to cause the control ring to exit the one or more notches; andcompletely withdrawing the microcatheter and the delivery tube from the patient.
US Referenced Citations (410)
Number Name Date Kind
2849002 Oddo Aug 1958 A
3480017 Shute Nov 1969 A
4085757 Pevsner Apr 1978 A
4282875 Serbinenko et al. Apr 1981 A
4364392 Strother et al. Dec 1982 A
4395806 Wonder et al. Aug 1983 A
4517979 Pecenka May 1985 A
4545367 Tucci Oct 1985 A
4836204 Landymore et al. Jun 1989 A
4991602 Amplatz et al. Feb 1991 A
5002556 Ishida Mar 1991 A
5025060 Yabuta et al. Jun 1991 A
5065772 Cox, Jr. Nov 1991 A
5067489 Lind Nov 1991 A
5122136 Guglielmi et al. Jun 1992 A
5192301 Kamiya et al. Mar 1993 A
5261916 Engelson Nov 1993 A
5304195 Twyford, Jr. et al. Apr 1994 A
5334210 Gianturco Aug 1994 A
5350397 Palermo Sep 1994 A
5423829 Pham et al. Jun 1995 A
5624449 Pham et al. Apr 1997 A
5645558 Horton Jul 1997 A
5733294 Forber et al. Mar 1998 A
5891128 Gia et al. Apr 1999 A
5916235 Guglielmi Jun 1999 A
5928260 Chin et al. Jul 1999 A
5935148 Villar Aug 1999 A
5941249 Maynard Aug 1999 A
5951599 McCrory Sep 1999 A
5964797 Ho Oct 1999 A
6007573 Wallace et al. Dec 1999 A
6024756 Pham Feb 2000 A
6036720 Abrams Mar 2000 A
6063070 Eder May 2000 A
6063100 Diaz et al. May 2000 A
6063104 Villar May 2000 A
6080191 Thaler Jun 2000 A
6086577 Ken et al. Jul 2000 A
6096021 Helm et al. Aug 2000 A
6113609 Adams Sep 2000 A
6123714 Gia et al. Sep 2000 A
6168615 Ken Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6193708 Ken et al. Feb 2001 B1
6221086 Forber Apr 2001 B1
6270515 Linden et al. Aug 2001 B1
6315787 Tsugita et al. Nov 2001 B1
6331184 Abrams Dec 2001 B1
6334048 Edvardsson et al. Dec 2001 B1
6346117 Greenhalgh Feb 2002 B1
6350270 Roue Feb 2002 B1
6375606 Garbaldi et al. Apr 2002 B1
6375668 Gifford Apr 2002 B1
6379329 Naglreiter et al. Apr 2002 B1
6391037 Greenhalgh May 2002 B1
6419686 McLeod et al. Jul 2002 B1
6428558 Jones Aug 2002 B1
6454780 Wallace Sep 2002 B1
6463317 Kucharczyk Oct 2002 B1
6506204 Mazzocchi Jan 2003 B2
6527919 Roth Mar 2003 B1
6547804 Porter et al. Apr 2003 B2
6551303 Van Tassel et al. Apr 2003 B1
6569179 Teoh May 2003 B2
6569190 Whalen, II et al. May 2003 B2
6572628 Dominguez Jun 2003 B2
6589230 Gia et al. Jul 2003 B2
6589256 Forber Jul 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6620152 Guglielmi Sep 2003 B2
6669719 Wallace et al. Dec 2003 B2
6689159 Lau et al. Feb 2004 B2
6746468 Sepetka Jun 2004 B1
6780196 Chin et al. Aug 2004 B2
6802851 Jones Oct 2004 B2
6811560 Jones Nov 2004 B2
6833003 Jones et al. Dec 2004 B2
6846316 Abrams Jan 2005 B2
6849081 Sepetka et al. Feb 2005 B2
6855154 Abdel-Gawwad Feb 2005 B2
6949116 Solymar et al. Sep 2005 B2
6964657 Cragg et al. Nov 2005 B2
6964671 Cheng Nov 2005 B2
6994711 Hieshima et al. Feb 2006 B2
7044134 Khairkhahan et al. May 2006 B2
7083632 Avellanet Aug 2006 B2
7093527 Rapaport et al. Aug 2006 B2
7128736 Abrams et al. Oct 2006 B1
7152605 Khairkhahan et al. Dec 2006 B2
7153323 Teoh Dec 2006 B1
7195636 Avellanet et al. Mar 2007 B2
7229454 Tran et al. Jun 2007 B2
7229461 Chin et al. Jun 2007 B2
7309345 Wallace Dec 2007 B2
7371249 Douk et al. May 2008 B2
7410482 Murphy Aug 2008 B2
7572288 Cox Aug 2009 B2
7597704 Frazier et al. Oct 2009 B2
7608088 Jones Oct 2009 B2
7695488 Berenstein Apr 2010 B2
7713264 Murphy May 2010 B2
7744652 Morsi Jun 2010 B2
7892248 Tran Feb 2011 B2
7985238 Balgobin et al. Jul 2011 B2
RE42758 Ken Sep 2011 E
8016852 Ho Sep 2011 B2
8021416 Abrams Sep 2011 B2
8025668 McCartney Sep 2011 B2
8034061 Amplatz et al. Oct 2011 B2
8048145 Evans et al. Nov 2011 B2
8062325 Mitelberg et al. Nov 2011 B2
8075585 Lee et al. Dec 2011 B2
8142456 Rosqueta Mar 2012 B2
8221483 Ford et al. Jul 2012 B2
8261648 Marchand et al. Sep 2012 B1
8267923 Murphy Sep 2012 B2
8361106 Solar et al. Jan 2013 B2
8361138 Adams Jan 2013 B2
8372114 Hines Feb 2013 B2
8398671 Chen Mar 2013 B2
8430012 Marchand Apr 2013 B1
8454633 Amplatz et al. Jun 2013 B2
8523897 van der Burg et al. Sep 2013 B2
8523902 Heaven et al. Sep 2013 B2
8551132 Eskridge et al. Oct 2013 B2
8777974 Amplatz et al. Jul 2014 B2
8900304 Alobaid Dec 2014 B1
8992568 Duggal et al. Mar 2015 B2
8998947 Aboytes et al. Mar 2015 B2
8974512 Aboytes et al. Apr 2015 B2
9055948 Jaeger et al. Jun 2015 B2
9107670 Hannes et al. Aug 2015 B2
9161758 Figulla et al. Oct 2015 B2
9232992 Heidner et al. Jan 2016 B2
9259337 Cox et al. Feb 2016 B2
9314326 Wallace et al. Apr 2016 B2
9351715 Mach May 2016 B2
9414842 Glimsdale et al. Aug 2016 B2
9526813 Cohn et al. Dec 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9532873 Kelley Jan 2017 B2
9533344 Monetti et al. Jan 2017 B2
9539011 Chen et al. Jan 2017 B2
9539022 Bowman Jan 2017 B2
9539122 Burke et al. Jan 2017 B2
9539382 Nelson Jan 2017 B2
9549830 Bruszewski et al. Jan 2017 B2
9554805 Tompkins et al. Jan 2017 B2
9561096 Kim et al. Feb 2017 B2
9561125 Bowman et al. Feb 2017 B2
9572982 Burnes et al. Feb 2017 B2
9579104 Beckham et al. Feb 2017 B2
9579484 Barnell Feb 2017 B2
9585642 Dinsmoor et al. Mar 2017 B2
9585669 Becking et al. Mar 2017 B2
9615832 Bose et al. Apr 2017 B2
9615951 Bennett et al. Apr 2017 B2
9622753 Cox Apr 2017 B2
9629635 Hewitt et al. Apr 2017 B2
9636115 Henry et al. May 2017 B2
9636439 Chu et al. May 2017 B2
9642675 Werneth et al. May 2017 B2
9655633 Leynov et al. May 2017 B2
9655645 Staunton May 2017 B2
9655989 Cruise et al. May 2017 B2
9662129 Galdonik et al. May 2017 B2
9662238 Dwork et al. May 2017 B2
9662425 Lilja et al. May 2017 B2
9668898 Wong Jun 2017 B2
9675477 Thompson Jun 2017 B2
9675782 Connolly Jun 2017 B2
9676022 Ensign et al. Jun 2017 B2
9681861 Heisel et al. Jun 2017 B2
9692557 Murphy Jun 2017 B2
9693852 Lam et al. Jul 2017 B2
9700262 Janik et al. Jul 2017 B2
9700399 Acosta-Acevedo Jul 2017 B2
9717421 Griswold et al. Aug 2017 B2
9717500 Tieu et al. Aug 2017 B2
9717502 Teoh et al. Aug 2017 B2
9724103 Cruise et al. Aug 2017 B2
9724526 Strother et al. Aug 2017 B2
9750565 Bloom et al. Sep 2017 B2
9757260 Greenan Sep 2017 B2
9764111 Gulachenski Sep 2017 B2
9770251 Bowman et al. Sep 2017 B2
9770577 Li et al. Sep 2017 B2
9775621 Tompkins et al. Oct 2017 B2
9775706 Paterson et al. Oct 2017 B2
9775732 Khenansho Oct 2017 B2
9788800 Mayoras, Jr. Oct 2017 B2
9795391 Saatchi et al. Oct 2017 B2
9801980 Karino et al. Oct 2017 B2
9808599 Bowman et al. Nov 2017 B2
9833252 Sepetka et al. Dec 2017 B2
9833604 Lam et al. Dec 2017 B2
9833625 Waldhauser et al. Dec 2017 B2
9918720 Marchand et al. Mar 2018 B2
9955976 Hewitt et al. May 2018 B2
10130372 Griffin Nov 2018 B2
10307148 Heisel et al. Jun 2019 B2
10327781 Divino et al. Jun 2019 B2
10342546 Sepetka et al. Jul 2019 B2
10716573 Connor Jul 2020 B2
20020068974 Kuslich et al. Jun 2002 A1
20020082638 Porter et al. Jun 2002 A1
20020143349 Gifford, III et al. Oct 2002 A1
20020147497 Belef et al. Oct 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20030028209 Teoh et al. Feb 2003 A1
20030120337 Van Tassel et al. Jun 2003 A1
20030171739 Murphy Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181927 Wallace Sep 2003 A1
20030181945 Opolski Sep 2003 A1
20030195553 Wallace Oct 2003 A1
20030216772 Konya Nov 2003 A1
20040034366 van der Burg et al. Feb 2004 A1
20040034386 Fulton et al. Feb 2004 A1
20040044391 Porter Mar 2004 A1
20040087998 Lee et al. May 2004 A1
20040098027 Teoh et al. May 2004 A1
20040127935 Van Tassel et al. Jul 2004 A1
20040133222 Tran et al. Jul 2004 A1
20040153120 Seifert et al. Aug 2004 A1
20040210297 Lin et al. Oct 2004 A1
20040254594 Alfaro Dec 2004 A1
20050021016 Malecki et al. Jan 2005 A1
20050021072 Wallace Jan 2005 A1
20050159771 Petersen Jul 2005 A1
20050177103 Hunter et al. Aug 2005 A1
20050251200 Porter Nov 2005 A1
20060052816 Bates et al. Mar 2006 A1
20060058735 Lesh Mar 2006 A1
20060064151 Guterman Mar 2006 A1
20060106421 Teoh May 2006 A1
20060155323 Porter et al. Jul 2006 A1
20060155367 Hines Jul 2006 A1
20060167494 Suddaby Jul 2006 A1
20060247572 McCartney Nov 2006 A1
20070088387 Eskridge et al. Apr 2007 A1
20070106311 Wallace May 2007 A1
20070208376 Meng Jun 2007 A1
20070162071 Burkett Jul 2007 A1
20070167876 Euteneuer et al. Jul 2007 A1
20070173928 Morsi Jul 2007 A1
20070186933 Domingo Aug 2007 A1
20070191884 Eskridge et al. Aug 2007 A1
20070233188 Hunt et al. Oct 2007 A1
20070265656 Amplatz Nov 2007 A1
20070288083 Hines Dec 2007 A1
20080097495 Feller, III et al. Apr 2008 A1
20080103505 Fransen May 2008 A1
20080281350 Sepetka Nov 2008 A1
20090036877 Nardone Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090099647 Glimsdale Apr 2009 A1
20090227983 Griffin et al. Sep 2009 A1
20090281557 Sander et al. Nov 2009 A1
20090287291 Becking et al. Nov 2009 A1
20090287297 Cox Nov 2009 A1
20090318941 Sepetka Dec 2009 A1
20100023046 Heidner et al. Jan 2010 A1
20100023048 Mach Jan 2010 A1
20100063573 Hijikema Mar 2010 A1
20100063582 Rudakov Mar 2010 A1
20100069948 Veznedaroglu Mar 2010 A1
20100168781 Berenstein Jul 2010 A1
20100324649 Mattsson et al. Dec 2010 A1
20110046658 Conner et al. Feb 2011 A1
20110054519 Neuss Mar 2011 A1
20110112588 Linderman et al. May 2011 A1
20110137317 O'Halloran et al. Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110196413 Wallace Aug 2011 A1
20110319978 Schaffer Dec 2011 A1
20120010644 Sideris et al. Jan 2012 A1
20120071911 Sadasivan Mar 2012 A1
20120165732 Müller Jun 2012 A1
20120191123 Brister et al. Jul 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120310270 Murphy Dec 2012 A1
20120323267 Ren Dec 2012 A1
20120330341 Becking et al. Dec 2012 A1
20130035665 Chu Feb 2013 A1
20130035712 Theobald et al. Feb 2013 A1
20130066357 Aboytes et al. Mar 2013 A1
20130079864 Boden Mar 2013 A1
20130110066 Sharma et al. May 2013 A1
20130204351 Cox et al. Aug 2013 A1
20130211495 Halden Aug 2013 A1
20130261658 Lorenzo et al. Oct 2013 A1
20130261730 Bose Oct 2013 A1
20130274863 Cox et al. Oct 2013 A1
20130345738 Eskridge Dec 2013 A1
20140005714 Quick et al. Jan 2014 A1
20140012307 Franano et al. Jan 2014 A1
20140012363 Franano et al. Jan 2014 A1
20140018838 Franano et al. Jan 2014 A1
20140135812 Divino et al. May 2014 A1
20140200607 Sepetka et al. Jul 2014 A1
20140257360 Keillor Sep 2014 A1
20140277013 Sepetka et al. Sep 2014 A1
20140358178 Hewitt et al. Dec 2014 A1
20150057703 Ryan et al. Feb 2015 A1
20150209050 Aboytes et al. Jul 2015 A1
20150272589 Lorenzo Oct 2015 A1
20150313605 Griffin Nov 2015 A1
20150342613 Aboytes et al. Dec 2015 A1
20150374483 Janardhan et al. Dec 2015 A1
20160022445 Ruvalcaba et al. Jan 2016 A1
20160030050 Franano et al. Feb 2016 A1
20160192912 Kassab et al. Jul 2016 A1
20160249934 Hewitt et al. Sep 2016 A1
20170007264 Cruise et al. Jan 2017 A1
20170007265 Guo et al. Jan 2017 A1
20170020670 Murray et al. Jan 2017 A1
20170020700 Bienvenu et al. Jan 2017 A1
20170027640 Kunis et al. Feb 2017 A1
20170027692 Bonhoeffer et al. Feb 2017 A1
20170027725 Argentine Feb 2017 A1
20170035436 Morita Feb 2017 A1
20170035567 Duffy Feb 2017 A1
20170042548 Lam Feb 2017 A1
20170049596 Schabert Feb 2017 A1
20170071737 Kelley Mar 2017 A1
20170072452 Monetti et al. Mar 2017 A1
20170079661 Bardsley et al. Mar 2017 A1
20170079662 Rhee et al. Mar 2017 A1
20170079671 Morero et al. Mar 2017 A1
20170079680 Bowman Mar 2017 A1
20170079717 Walsh et al. Mar 2017 A1
20170079766 Wang et al. Mar 2017 A1
20170079767 Leon-Yip Mar 2017 A1
20170079812 Lam et al. Mar 2017 A1
20170079817 Sepetka et al. Mar 2017 A1
20170079819 Pung et al. Mar 2017 A1
20170079820 Lam et al. Mar 2017 A1
20170086851 Wallace et al. Mar 2017 A1
20170086996 Peterson et al. Mar 2017 A1
20170095259 Tompkins et al. Apr 2017 A1
20170100126 Bowman et al. Apr 2017 A1
20170100141 Morero et al. Apr 2017 A1
20170100143 Granfield Apr 2017 A1
20170100183 Iaizzo et al. Apr 2017 A1
20170113023 Steingisser et al. Apr 2017 A1
20170114350 dos Santos et al. Apr 2017 A1
20170147765 Mehta May 2017 A1
20170151032 Loisel Jun 2017 A1
20170165062 Rothstein Jun 2017 A1
20170165065 Rothstein et al. Jun 2017 A1
20170165454 Tuohy et al. Jun 2017 A1
20170172581 Bose et al. Jun 2017 A1
20170172766 Vong et al. Jun 2017 A1
20170172772 Khenansho Jun 2017 A1
20170189033 Sepetka et al. Jul 2017 A1
20170189035 Porter Jul 2017 A1
20170215902 Leynov et al. Aug 2017 A1
20170216484 Cruise et al. Aug 2017 A1
20170224350 Shimizu et al. Aug 2017 A1
20170224355 Bowman et al. Aug 2017 A1
20170224467 Piccagli et al. Aug 2017 A1
20170224511 Dwork et al. Aug 2017 A1
20170224953 Tran et al. Aug 2017 A1
20170231749 Perkins et al. Aug 2017 A1
20170252064 Staunton Sep 2017 A1
20170265983 Lam et al. Sep 2017 A1
20170281192 Tieu et al. Oct 2017 A1
20170281331 Perkins et al. Oct 2017 A1
20170281344 Costello Oct 2017 A1
20170281909 Northrop et al. Oct 2017 A1
20170281912 Melder et al. Oct 2017 A1
20170290593 Cruise et al. Oct 2017 A1
20170290654 Sethna Oct 2017 A1
20170296324 Argentine Oct 2017 A1
20170296325 Marrocco et al. Oct 2017 A1
20170303939 Greenhalgh et al. Oct 2017 A1
20170303942 Greenhalgh et al. Oct 2017 A1
20170303947 Greenhalgh et al. Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170304041 Argentine Oct 2017 A1
20170304097 Corwin et al. Oct 2017 A1
20170304595 Nagasrinivasa et al. Oct 2017 A1
20170312109 Le Nov 2017 A1
20170312484 Shipley et al. Nov 2017 A1
20170316561 Helm et al. Nov 2017 A1
20170319826 Bowman et al. Nov 2017 A1
20170333228 Orth et al. Nov 2017 A1
20170333236 Greenan Nov 2017 A1
20170333678 Bowman et al. Nov 2017 A1
20170340333 Badruddin et al. Nov 2017 A1
20170340383 Bloom et al. Nov 2017 A1
20170348014 Wallace et al. Dec 2017 A1
20170348514 Guyon et al. Dec 2017 A1
20180140305 Connor May 2018 A1
20180242979 Lorenzo Aug 2018 A1
20180303531 Sanders et al. Oct 2018 A1
20180338767 Dasnurkar et al. Nov 2018 A1
20190008522 Lorenzo Jan 2019 A1
20190223878 Lorenzo et al. Jan 2019 A1
20190110796 Jayaraman Apr 2019 A1
20190192162 Lorenzo Jun 2019 A1
20190192167 Lorenzo Jun 2019 A1
20190192168 Lorenzo Jun 2019 A1
20190223879 Jayaraman Jul 2019 A1
20190223881 Hewitt et al. Sep 2019 A1
20190328398 Lorenzo Oct 2019 A1
20190365385 Gorochow et al. Dec 2019 A1
20200268365 Hebert et al. Aug 2020 A1
Foreign Referenced Citations (95)
Number Date Country
2395796 Jul 2001 CA
2 431 594 Sep 2002 CA
2598048 May 2008 CA
204 683 687 Jul 2015 CN
102008015781 Oct 2009 DE
102010053111 Jun 2012 DE
102011102955 Dec 2012 DE
102009058132 Jul 2014 DE
202008018523 Apr 2015 DE
102013106031 Jul 2015 DE
09027048 Mar 1999 EP
1054635 Nov 2000 EP
1295563 Mar 2003 EP
1441649 Aug 2004 EP
1483009 Aug 2004 EP
1494619 Jan 2005 EP
1527753 May 2005 EP
1569565 Jul 2005 EP
1574169 Sep 2005 EP
1633275 Mar 2006 EP
1659988 May 2006 EP
1725185 Nov 2006 EP
1862122 Dec 2007 EP
1923005 May 2008 EP
2063791 Mar 2009 EP
2134263 Dec 2009 EP
2157937 Mar 2010 EP
2266456 Dec 2010 EP
2324775 May 2011 EP
2367482 Sep 2011 EP
2387951 Nov 2011 EP
2460476 Jun 2012 EP
2468349 Jun 2012 EP
2543345 Jan 2013 EP
2567663 Mar 2013 EP
2617386 Jul 2013 EP
2623039 Aug 2013 EP
2647343 Oct 2013 EP
2848211 Mar 2015 EP
2854704 Apr 2015 EP
2923674 Sep 2015 EP
2926744 Oct 2015 EP
3146916 Mar 2017 EP
3501429 Jun 2019 EP
3517055 Jul 2019 EP
H04-47415 Apr 1992 JP
H07-37200 Jul 1995 JP
2006-509578 Mar 2006 JP
2013-509972 Mar 2013 JP
2013537069 Sep 2013 JP
2016-502925 Feb 2015 JP
WO9641589 Dec 1996 WO
9905977 Feb 1999 WO
WO9908607 Feb 1999 WO
WO 9930640 Jun 1999 WO
2003073961 Sep 2003 WO
WO 2003073961 Sep 2003 WO
WO 03086240 Oct 2003 WO
WO2005020822 Mar 2005 WO
WO 2005074814 Aug 2005 WO
WO 2005117718 Dec 2005 WO
WO2006034149 Mar 2006 WO
WO2006052322 May 2006 WO
2007076480 Jul 2007 WO
WO 2008150346 Dec 2008 WO
WO 2008151204 Dec 2008 WO
WO2009048700 Apr 2009 WO
WO2009105365 Aug 2009 WO
WO2009132045 Oct 2009 WO
WO2009135166 Nov 2009 WO
WO2010030991 Mar 2010 WO
WO2011057002 May 2011 WO
WO2012032030 Mar 2012 WO
WO2012099704 Jul 2012 WO
WO2012099909 Jul 2012 WO
WO2012113554 Aug 2012 WO
WO2013016618 Jan 2013 WO
WO2013025711 Feb 2013 WO
WO2013109309 Jul 2013 WO
WO 2013159065 Oct 2013 WO
WO2014029835 Feb 2014 WO
WO2014110589 Jul 2014 WO
WO2014137467 Sep 2014 WO
WO2015073704 May 2015 WO
WO2015160721 Oct 2015 WO
WO2015166013 Nov 2015 WO
WO 2015171268 Nov 2015 WO
WO2015184075 Dec 2015 WO
WO2015187196 Dec 2015 WO
2016044647 Mar 2016 WO
WO2016107357 Jul 2016 WO
WO16137997 Sep 2016 WO
WO 2017161283 Sep 2017 WO
WO 2018051187 Mar 2018 WO
WO 2012034135 Mar 2021 WO
Non-Patent Literature Citations (4)
Entry
Altes et al., Creation of Saccular Aneurysms in the Rabbit: A Model Suitable for Testing Endovascular Devices. AJR 2000; 174: 349-354.
Schaffer, Advanced Materials & Processes, Oct. 2002, pp. 51-54.
Extended European Search Report issued in corresponding European Patent Application No. 19196722.3 dated Jan. 22, 2020.
Extended European Search Report issued in corresponding European Patent Application No. 19 21 5277 dated May 12, 2020.
Related Publications (1)
Number Date Country
20150272589 A1 Oct 2015 US